

Figure S1. Cell migration and invasion assays in LUSQ cells with ectopic expression of *miR-150-5p* or *miR-150-3p*. (A) In wound healing assay, Phase-contrast micrographs of EBC-1 and SK-MES-1 cell lines transfected with *miR-150-5p* or *-3p* are shown. (B) Micrographs of LUSQ cells after transfection with *miR-150-5p* or *miR-150-3p* in Matrigel invasion assays are shown.




Figure S2. Cell proliferation was assessed with XTT assays after transfection of *miR-150-5p*, *-3p* or *5p + 3p*. Synergistic effects were not observed by combination of *miR-150-5p* and *miR-150-3p*. * $p < 0.05$, ** $p < 0.001$, *** $p < 0.01$, N.S.: not significant.




Figure S3. Downregulation of HELLS protein expression by *miR-150-3p*. Western blotting was performed to assay expression of HELLS protein. Full images of western blotting are shown. The western blotting results were quantified by ImageJ.

Homo sapiens helicase, lymphoid specific (HELLS), transcript variant 2, mRNA
 NCBI Reference Sequence: NM_001289067.2
 CDS 135–2789

```

1  gaaggagaag cgcgcttttt tccctggcgg gggatttggc tagaaggctg ggcgggcagc
61  ggttgtgagg agtttagctcg cggcattgca ggctctgaga ggaggggacc cggttcccgg
121  gtgagtgtcc aggcatgcga cgggaacggc ccgcgggcag cggcggtctg gaggtccag
181  caatggttga acaactggac actgctgtga ttaccccggc catgctagaa gaggaagaac
241  agcttgaagc tgcctgacta gagagagagc ggaagatgct ggaagaggtc cgcattgtctt
301  gggatagaga gtcgacagaa attcgggtacc gtagacttca acatttgctt gaaaaagca
361  atataactc caaattttta ttgacgaaaa tggacacagca acaattagag gaacagaaga
421  agaaaagaaa attggagaga aaaaaggagt ctttaaaagt taaaaagggt aaaaattcaa
481  ttgatgcaag tgaagagaag ccagttatga ggaaaaaaag aggaagagaa gatgaatcat
541  acaatatttc agaggtcatg tcaaaaagagg aaattttgtc tgtggctaaa aaaaataaaa
601  aggagaatga ggatgaaaac tccctcctca ctaatctctg tgtggaagat cttcagaaaa
661  ataaagattc gaatagtata attaaagata gattgtctga aacggttagg cagaatacta
721  aattcttttt tgaccagtc cgggaagtga atggtcagcc agtacctttt caacaacca
781  agcacttcac tggaggagtg atgcgatggt accaagtaga aggcattgaa tggcttagga
841  tgctttggga aaatggaatt aatggcattt tagcagatga aatgggattg ggtaagacag
901  ttcagtgcac tgctactatt gcattgatga ttcagagagg agtaccagga ccttttcttg
961  tctgtggccc tttgtctaca cttcctaact ggatggctga attcaaaaga ttacaccag
1021  atatccctac aatggtatata catggaaccc aggaggaaacg tcaaaaattg gtaagaaata
1081  tttcaaaacg gaaagggact ttgcagattc atcctgtggt aatcacgtca tttgaaatag
1141  ccatgagaga ccgaaatgcg ttacagcatt gctattggaa atacttaata gtagatgaag
1201  gacacaggat taagaatag aagtgcctgc taatcaggga gttaaaaacga ttcaatgctg
1261  ataacaaact tcttttgact ggtactccct tgcaaaacaa tttatcagaa ctttggtcat
1321  tgctaaactt tttgttgcca gatgtatttg atgacttgaa aagctttgag tcttggttg
1381  acatcactag tctttctgaa actgctgaag atattattgc taaagaaaga gaacagaatg
1441  tattgcatat gctgcaccag gaaagaattc ctagaatgta tgtgtcagag ttacagatg
1501  agggcttctt tgaaggcaaa ttgcctcca gaaaagattt atatgatata cgtccatag
1561  aaaaatacta tttactcaag cttcatacca attttgagat ttaaacacct ttcttattga
1621  gaagactgaa gtctgatgtt gctcttgaa ttccctccta acgagaagta gtcgttatg
1681  ctccactttc aaagaagcag gagatctttt atacagccat tgtgaaccgt acaattgcga
1741  acatgtttgg atccagtgag aaagaaacaa ttgagttaag tccactactg cgaacaaaac
1801  gacgaactag aaaaatcaata aattacagca aaatagatga ttccctaat gaattggaaa
1861  aactgatcag tcaaatacag ccagaggtgg accgagaaag agctgttggt gaagtgaata
1921  tccctgtaga atctgaagt aatctgaagc tgcagaatat aatgatgcta cttcgttaat
1981  gttgtaatca tccatatttg attgaatata ctatagacc tgttacacaa gaatttaaga
2041  tcgatgaaga attggttaaca aattctggga agttcttgat tttggatcga atgctgccag
2101  aactaaaaaa aagaggtcac aaggtgctgc ttttttcaca aatgacaagc atgttgga
2161  ttttgatgga ttactgcca ctcagagatt tcaacttcag caggcttgat gggcccatgt
2221  ctactcaga gagagaaaaa aacatgcaca gtttcaacac ggatccagag gtgtttatct
2281  tcttagtgag tacacgagct ggtggcctgg gcattaatct gactgcagca gatcacagta
2341  tcatttatga tagtgattgg aacccccagt cggatcttca ggcccaggat agatgtcata
2401  gaattggtca gacaaagcca gttgttgttt atcgcttgtg tacagcaaat actatcgatc
2461  agaaaattgt ggaagagca gctgctaaaa ggaactgga aaagttgatc atccataaaa
2521  atcatttcaa aggtggtcag tctggattaa atctgtctaa gaatttctta gatcctaagg
2581  aattaatgga attattaaaa tctagagatt atgaaaggga aataaaaagg tcaagagaga
2641  aggtcattag tgataaagat ctagagttgt tgttagatcg aagtgatctt attgatcaaa
2701  tgaatgcttc aggaaccaatt aaagagaaga tggggatatt caagatatta gaaaattctg
2761  aagattccag tccatgaatg ttgttttaa gtggagctca agaatagctt ttaaaagttc
2821  ttattttacat ctagtatttt cccctgattg ggtttgaaat actgattgtc cacttcacct
2881  tttttattat atcagttgac atgtaactag taccatgcgt acttaaatag atggtaattt
2941  tctgagcctt accaagaaca aagaagtatc catattaaat ttagattttc agttaatttt
3001  tgagactgag tagtattctt ggatacaggc tgatgtgtac ttaaccactt ccagatttat
3061  acagtcttcc tgtggaagtt tagtaaatgt ctttttccct cctttcttct agtaatgcag
3121  ttcatgggct ttaggtactt cagttatgaa gtaggctttt catggggaga gattgggatt
3181  atgctctctg ttgtttaaga aactgtttga ttttagagtc tatttctatg agatagttta
3241  ccaataaat gttccttata agatga

```

Figure S4. The nucleotide sequence of *HELLS* gene (NM_001289067.2). The first methionine (atg) and stop codon (taa) are shown in red. The binding sequences of *miR-150-3p* (gtacca) is shown in bold red.





Figure S5. The sequence of the region containing the *miR-150-3p* binding site of each cell line. In each cell, a *miR-150-3p* binding sequence (gtacca) is present (red underline). This sequence was inserted into the luciferase reporter assay vector.

EBC-1



SK-MES-1




Figure S6. HELLs protein expression downregulated by si-HELLs. HELLs protein expression was evaluated by western blot. Full western blot images of HELLs are shown. The western blotting results were quantified by ImageJ.




Figure S7. Cell migration and invasion assays in EBC-1 and SK-MES-1 after knockdown of HELLS by si-HELLS. (A) Phase-contrast micrographs of wound healing assay are shown after transfection with si-HELLS in EBC-1 and SK-MES-1. (B) Micrographs of Matrigel invasion assays for LUSQ cells transfected with si-HELLS are shown.




Figure S8. Kaplan–Meier curves of 5-year overall survival due to difference in *HELLS* expression in LUSQ and LUAD patients from TCGA database and forest plot presenting the results of a multivariate Cox regression analysis of the prognostic value of *HELLS* in TCGA-LUSQ and TCGA-LUAD. 5-year overall survival showed that low expression of *HELLS* was poor prognosis in LUSQ patients, but on the other hand high expression of *HELLS* was poor prognosis in LUAD. The expression level of *HELLS* was determined to be independent prognostic factors in terms of the 5-year overall survival rate after adjustments for age, sex, disease stage, pathological T and N stage ($p < 0.05$). HR: hazard ratio, CI: confidence interval.

Table S1: Reagents used in this study.

Primer and probe		Assay ID	Company
<i>miR-150-5p</i>		000473	Applied Biosystem (Foster City, CA, USA)
<i>miR-150-3p</i>		002637	Applied Biosystem
<i>RNU48</i>		001006	Applied Biosystem
<i>HELLS</i>		Hs00934778_m1	Applied Biosystem
<i>GUSB</i>		Hs00939627_m1	Applied Biosystem
miRNA	Concentration	Catalog Number/Assay ID	Company
<i>miR-150-5p</i>	10nM	AM17100 / PM10070	Invitrogen (Carlsbad, CA, USA)
<i>miR-150-3p</i>	10nM	AM17100 / PM12324	Invitrogen
anti-miR Negative Control #1	10nM	AM17010 / AM1--100	Invitrogen
siRNA	Concentration	Primer Name	Company
<i>si-HELLS</i>	10nM	HSS104740, HSS104741, HSS179196	Invitrogen (Carlsbad, CA, USA)
Antibody	Dilution	Catalog number	company
HELLS (SMARCA6)	WB 1:500	ab3851	Abcam (Cambridge, UK)
GAPDH	WB 1:10000	MAB374	EMD Millipore (Billerica, MA, USA)
HELLS	IHC 1:200	HPA063242	Sigma Aldrich (St. Louis, MO, USA)

Table S2: Characteristics of the patients used for normal lung tissue near the tumor in Figure 2A.

Age	Sex	T	N	M	Pathological stage	Type
64	M	1a	1	0	IIA	LUSQ
70	M	2a	1	0	IIA	LUSQ
69	M	3	0	0	IIB	LUSQ
78	M	1a	1	0	IIA	LUSQ
78	M	2b	2a	0	IIIA	LUSQ
79	M	3	1	0	IIIA	LUSQ
61	M	3	1	0	IIIA	LUSQ
75	M	1a	0	0	IA	LUSQ
50	M	1a	2	0	IIIA	LUSQ
73	M	2a	0	0	IB	LUSQ
64	M	2a	0	0	IB	LUSQ
88	M	3	0	0	IIB	LUSQ
68	M	3	0	0	IIB	LUSQ
76	M	1b	0	0	IA	LUSQ
73	M	2a	0	0	IB	LUSQ
76	M	2a	0	0	IB	LUSQ
65	M	1b	0	0	IA	LUSQ
69	M	1b	0	0	IA	LUSQ
50	M	2a	0	0	IB	LUSQ
65	M	2a	0	0	IB	LUSQ
69	M	1a	0	0	IA	LUSQ
65	M	2a	0	0	IB	LUSQ

LUSQ: lung squamous cell carcinoma.

Table S3: Characteristics of the patients used for lung cancer tissue in Figure 2A.

Age	Sex	T	N	M	Pathological stage	Type
69	M	3	0	0	IIB	LUSQ
65	M	3	0	0	IIB	LUSQ
71	M	3	2	0	IIIA	LUSQ
78	M	2b	2a	0	IIIA	LUSQ
56	M	2a	1	0	IIA	LUSQ
79	M	3	1	0	IIIA	LUSQ
61	M	3	1	0	IIIA	LUSQ
50	M	1a	2	0	IIIA	LUSQ
74	M	3	0	0	IIB	LUSQ
73	M	2a	0	0	IB	LUSQ
64	M	2a	0	0	IB	LUSQ
88	M	3	0	0	IIB	LUSQ
68	M	3	0	0	IIB	LUSQ
65	F	1b	2	0	IIB	LUSQ
72	M	2a	1	0	IIA	LUSQ
76	M	1b	0	0	IA	LUSQ
71	M	2a	2	0	IIIA	LUSQ
73	M	2a	0	0	IB	LUSQ
73	M	2a	0	0	IB	LUSQ
71	M	2b	2	0	IIIA	LUSQ
77	M	1a	0	0	IA	LUSQ
73	F	3a	0	0	IIB	LUSQ
82	M	2a	0	0	IB	LUSQ
76	M	2a	0	0	IB	LUSQ
65	M	1b	0	0	IA	LUSQ
69	M	1b	0	0	IA	LUSQ
50	M	2a	0	0	IB	LUSQ
65	M	2a	0	0	IB	LUSQ
69	M	1a	0	0	IA	LUSQ
50	M	4	2	0	IIIB	LUSQ
65	M	2a	0	0	IB	LUSQ

LUSQ: lung squamous cell carcinoma.

Table S4: Characteristics of the patients used for immunostaining.

Patients	Age	Sex	T	N	M	Pathological stage	Type
A	69	M	1	0	0	IA	LUSQ
B	48	M	2	0	0	IB	LUSQ
C	54	M	3	0	0	IIB	LUSQ
D	30	M	-	-	-	-	Normal lung tissue
E	24	M	-	-	-	-	Normal lung tissue
F	48	M	-	-	-	-	Normal lung tissue

LUSQ: lung squamous cell carcinoma.